Name of Policy: Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer

Transcription

1 Name of Policy: Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer Policy #: 401 Latest Review Date: November 2013 Category: Surgery Policy Grade: A Background/Definitions: As a general rule, benefits are payable under Blue Cross and Blue Shield of Alabama health plans only in cases of medical necessity and only if services or supplies are not investigational, provided the customer group contracts have such coverage. The following Association Technology Evaluation Criteria must be met for a service/supply to be considered for coverage: 1. The technology must have final approval from the appropriate government regulatory bodies; 2. The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes; 3. The technology must improve the net health outcome; 4. The technology must be as beneficial as any established alternatives; 5. The improvement must be attainable outside the investigational setting. Medical Necessity means that health care services (e.g., procedures, treatments, supplies, devices, equipment, facilities or drugs) that a physician, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury or disease or its symptoms, and that are: 1. In accordance with generally accepted standards of medical practice; and 2. Clinically appropriate in terms of type, frequency, extent, site and duration and considered effective for the patient s illness, injury or disease; and 3. Not primarily for the convenience of the patient, physician or other health care provider; and 4. Not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient s illness, injury or disease. Page 1 of 8

2 Description of Procedure or Service: The use of hematopoietic stem-cell transplantation (HSCT) has been investigated for treatment of patients with epithelial ovarian cancer. Hematopoietic stem cells are infused to restore bone marrow function following cytotoxic doses of chemotherapeutic agents with or without whole body radiation therapy. Hematopoietic Stem-Cell Transplantation Hematopoietic stem-cell transplantation (HSCT) refers to a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer patients who receive bone marrow toxic doses of cytotoxic drugs with or without whole body radiation therapy. Bone marrow stem cells may be obtained from the transplant recipient (autologous HSCT) or from a donor (allogeneic HSCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood and placenta shortly after delivery of neonates. Although cord blood is an allogeneic source, the stem cells in it are antigenically naïve and thus are associated with a lower incidence of rejection or graft-versus-host disease. HSCT is an established treatment for certain hematologic malignancies; however, its use in solid tumors in adults continues to be largely experimental. Initial enthusiasm for the use of autologous transplant with the use of high-dose chemotherapy and stem cells for solid tumors has waned with the realization that dose intensification often fails to improve survival, even in tumors with a linear-dose response to chemotherapy. With the advent of reduced-intensity conditioning (RIC) allogeneic transplant, interest has shifted to exploring the generation of alloreactivity to metastatic solid tumors via a graft-versus-tumor effect of donor-derived T cells. Epithelial Ovarian Cancer Several different types of malignancies can arise in the ovary; epithelial carcinoma is the most common. Epithelial ovarian cancer is the fifth most common cause of cancer death in women. New cases and deaths from ovarian cancer in the United States in 2013 are estimated at 22,240 and 14,030. Most ovarian cancer patients present with widespread disease, and yearly mortality is approximately 65% of the incidence rate. Current management of advanced epithelial ovarian cancer is cytoreductive surgery followed by combination chemotherapy. Approximately 75% of patients present with International Federation of Gynecology and Obstetrics (FIGO) stage III or IV ovarian cancer, and treated with the combination of paclitaxel and a platinum analog being the preferred regimen for newly diagnosed advanced disease. The use of platinum and taxanes has improved progression-free survival (PFS) and overall survival (OS) rates in advanced disease to months and months, respectively. However, most of these women develop recurrences and die of their disease as chemotherapy drug resistance leads to uncontrolled cancer growth. High-dose chemotherapy has been investigated as a way to overcome drug resistance. However, limited data exist on this treatment approach, and the ideal patient population and best regimen remain to be established. Hematopoietic stem-cell transplantation has been studied in a variety of patient groups with ovarian cancer as follows: Page 2 of 8

3 to consolidate remission after initial treatment to treat relapse after a durable response to platinum-based chemotherapy to treat tumors that relapsed after less than 6 months to treat refractory tumors Policy: Autologous or allogeneic hematopoietic stem-cell transplantation does not meet Blue Cross and Blue Shield of Alabama s medical criteria for coverage and is considered investigational to treat epithelial ovarian cancer. Blue Cross and Blue Shield of Alabama does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Cross and Blue Shield of Alabama administers benefits based on the members' contract and corporate medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination. Key Points: A 1998 TEC Assessment, High-dose chemotherapy with autologous stem cell support for epithelial ovarian cancer reached the following conclusions: Data were unavailable from randomized controlled trials for any of the patient groups studied. Thus, the Assessment was able to compare outcomes only indirectly, using separate studies of high-dose chemotherapy (HDC) and conventional dose regimens. Although some results reported after high-dose therapy appeared encouraging, the indirect comparisons did not permit conclusions. In previously untreated patients, reported response rates suggested that high-dose therapy increased the objective response rate compared to patients given conventional-dose chemotherapy. However, this comparison was flawed by age bias and by differences in performance status and other baseline characteristics of patients included in the two sets of studies. Response duration and survival data were unavailable for comparison. Treatment-related mortality was greater after high-dose therapy. In previously treated patients, objective response rates after HDC also were reportedly higher than after conventional-dose regimens. Subgroup analyses showed higher response rates among platinum-sensitive, optimally debulked patients. Minimum values of the ranges reported across studies for median response duration and survival after HDC were similar to those reported after conventional-dose chemotherapy. However, the maxima for these ranges suggested improved response duration and overall survival after high-dose therapy. In contrast, data from the Autologous Blood and Marrow Transplant Registry did not show similarly high survival for comparable subgroups. Comparison with conventional-dose chemotherapy was again biased due to differences in Page 3 of 8

4 age distributions, performance status, and other baseline characteristics of patients included in studies of high-dose or conventional therapies. The 1998 TEC Assessment did not identify any studies reporting outcomes of allogeneic transplants for patients with ovarian cancer. A separate 1999 TEC Assessment evaluated the use of HDC with allogeneic stem-cell support (HDC/AlloSCS) as salvage therapy after a failed prior course of HDC/AuSCS. There were no data regarding outcomes of this strategy as therapy for epithelial ovarian cancer. Experience with HSCT in epithelial ovarian cancer comes primarily from registry data and phase II trials. Over the last 20 years, more than 1,000 patients have been entered on transplant registries in Europe and in the U.S. Many of the registry patients were treated in relapse, and others in nonrandomized studies using HDC as first-line treatment. Case selection and retrospective review make the interpretation of the registries and nonrandomized data difficult. Survival analyses from registry data and clinical trials suggested a possible benefit treating ovarian cancer patients with HSCT. However, as outlined here, none of the randomized trials that have been performed have provided evidence that HSCT in ovarian cancer provides any outcome benefit. In 2012, Sabatier et al. reported on a retrospective review of 163 patients with advanced or metastatic (Federation of Gynecology and Obstetrics [FIGO] stage IIIc-IV) epithelial ovarian cancer who were treated at a single institution in France. All patients received cytoreductive surgery and combination platinum/taxane chemotherapy. Investigators compared progressionfree survival (PFS) and overall survival (OS) between 60 patients who received subsequent highdose chemotherapy with autologous HSCT support and 103 patients who did not. High-dose chemotherapy regimens varied, but all contained alkylating agents. At a median follow-up of 47.5 months, PFS in the high-dose and standard chemotherapy groups was 20.1 months and 18.1 months, respectively (p value not reported). OS was 47.3 months and 41.3 months, respectively (p=0.29). In pre-specified subgroup analyses, median PFS was significantly longer in women younger than age 50 years who received high-dose chemotherapy compared with women who received standard chemotherapy (81.7 months vs. 11 months; p=0.02); in women older than 50 years, median PFS did not differ statistically between groups (17.9 months vs months; p=0.81). Similarly, median OS was significantly longer in women younger than age 50 years who received high-dose chemotherapy compared with women who received standard chemotherapy (54.6 months vs. 36 months; p=0.05) but not in women older than 50 years (49.5 months vs. 42 months; p value not reported). The authors recommended further study of highdose chemotherapy with autologous HSCT support in patients younger than 50 years. In 2008, Papadimitriou and colleagues reported on the use of HDC with stem-cell support as consolidation therapy in patients with advanced epithelial ovarian cancer (FIGO stage IIC-IV). Patients who achieved first clinical complete remission after conventional chemotherapy were randomly assigned to receive or not receive high-dose melphalan and autologous stem-cell transplant. A total of 80 patients were enrolled in the trial. Of the 37 patients allocated to HDC, 11 did not receive the treatment either due to refusal or failure of peripheral blood stem-cell Page 4 of 8

5 mobilization. In an intent-to-treat analysis, there were no significant differences between the two arms in time-to-disease progression (p=0.059) or OS (p=0.38). In 2007, Mobus et al reported on a trial of 149 patients with untreated ovarian cancer who were randomly assigned, after debulking surgery, to standard chemotherapy or sequential HDC and peripheral blood stem-cell support. This was the first randomized trial comparing HDC to standard CT as first-line treatment of ovarian cancer, and the investigators found no statistically significant difference in progression-free survival (PFS) or overall survival (OS) between the two treatment options. The median patient age was 50 years (range: 20 65) and FIGO stage was IIb/IIc in 4%, III in 78%, and IV in 17%. Seventy-six percent of patients in the HDC arm received all of the scheduled chemotherapy cycles. After a median follow-up of 38 months, PFS was 20.5 months in the standard chemotherapy arm and 29.6 months in the HDC arm (hazard ratio [HR]: 0.84; 95% confidence interval [CI]: ; p=0.40). Median OS was 62.8 months in the standard chemotherapy arm and 54.4 months in the HDC arm (HR: 1.17; 95% CI: ; p=0.54). In 2004, Cure et al reported on outcomes in advanced ovarian cancer patients randomized after second-look surgery to receive either HDC with peripheral blood stem-cell support or conventional-dose maintenance chemotherapy. These results were presented in abstract form and have yet to be published. Patients were younger than 60 years old with FIGO stage III-IV and disease sensitive to first-line chemotherapy. Enrolled were 110 patients (n=57 high-dose and n=53 conventional-dose chemotherapy). Median follow-up was 60 months. No difference was seen in disease-free or OS between the two arms. Disease-free survival in the conventionalversus high-dose group was 12.2 months (95% CI: ) versus 17.5 months (95% CI: ) (p=0.22). OS was 42.5 months (95% CI: ) and 49.7 months (95% CI: ), respectively (p=0.43). Summary Evidence for the use of hematopoietic stem-cell transplant (HSCT) as an adjunct to high-dose chemotherapy in epithelial ovarian cancer is based on three published randomized trials and data from case series and registries. At present, the evidence is insufficient to recommend this intervention either as first-line therapy or for patients in whom epithelial ovarian cancer has relapsed following standard chemotherapy. Therefore, the use of HSCT in epithelial ovarian cancer remains investigational. National Comprehensive Cancer Network (NCCN) Guidelines National Comprehensive Cancer Network clinical practice guidelines for epithelial ovarian cancer do not address a role for HSCT. Key Words: High-Dose Chemotherapy, Ovarian, Epithelial Approved by Governing Bodies: Not applicable Page 5 of 8

6 Benefit Application: Coverage is subject to member s specific benefits. Group specific policy will supersede this policy when applicable. ITS: Home Policy provisions apply FEP: FEP does not consider investigational if FDA approved. Will be reviewed for medical necessity. Pre-certification requirements: Not applicable Current Coding: CPT Codes: Management of recipient hematopoietic cell donor search and cell acquisition Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing; per donor ;thawing of previously frozen harvest, with washing; per donor ;specific cell depletion with harvest, T-cell depletion ;tumor cell depletion ;red blood cell removal ;platelet depletion ;plasma (volume) depletion ;cell concentration in plasma, mononuclear, or buffy coat layer Bone marrow; aspiration only Bone marrow; biopsy, needle or trocar Bone marrow harvesting for transplantation; allogeneic ; autologous (Effective January 1, 2012) Bone marrow or blood-derived peripheral stem-cell transplantation; allogeneic Bone marrow or blood-derived peripheral stem-cell transplantation; autologous Bone marrow or blood-derived peripheral stem-cell transplantation; allogeneic donor lymphocyte infusions HCPCS: S2140 S2142 Cord blood harvesting for transplantation, allogeneic Cord blood derived stem-cell transplantation, allogeneic Page 6 of 8

7 S2150 Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, highdose chemotherapy, and the number of days of post-transplant care on the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services) References: 1. Cure H, Battista C, Guastalla JP, et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. Abstract No: American Society for Clinical Oncology. 40th annual meeting. New Orleans, Louisiana. June 5-8, Donato ML, Aleman A, Champlin RE, et al. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 2004; 33(12): Ledermann JA, Herd R, Maraninchi D, et al. High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2001; 12(5): Mobus V, Wandt H, Frickhofen N, et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: Intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol 2007; 25(27): National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Ovarian Cancer. Version Accessed September Physician Data Query (PDQ), Ovarian epithelial cancer treatment (PDQ ). National Cancer Institute, U.S. National Institute of Health. Available online at: 7. Papadimitriou C, Dafni U, Anagnostopoulos A, et al. High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: Results of a single-institution randomized trial. Bone Marrow Transplant 2008; 41(6): Sabatier R, Goncalves A, Bertucci F et al. Are there candidates for high-dose chemotherapy in ovarian carcinoma? J Exp Clin Cancer Res 2012; 31: Stiff PJ, Veum-Stone J, Lazarus HM, et al. High-dose chemotherapy and autologous stemcell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med 2000; 133(7): Stiff PJ, Bayer R, Kerger C, et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 15(4): Policy History: Medical Policy Group, January 2010 (2) Medical Policy Administration Committee, January 2010 Page 7 of 8

8 Available for comment January 26-March 11, 2010 Medical Policy Group, November 2010 (1): Description updated, Key Points updated, no policy change Medical Policy Group, December 2011 (3): 2012 Code Updates: Verbiage update to Codes 38208, & 38230; Added Code Medical Policy Group, February 2012 (2): Updated Description and Key Points Medical Policy Group, January 2013 (2): 2013 Update to Key Points. No change in the policy statement. Medical Policy Panel, November 2013 Medical Policy Group, November 2013 (3): Update to Description, Key Points and References; no change in policy statement This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a caseby-case basis according to the terms of the member s plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment. This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review)in Blue Cross and Blue Shield s administration of plan contracts. Page 8 of 8